«Back

Class 2 Recall on Co-Amoxiclav 125 Mg/31.25 Mg/5 Ml & 25 Mg/62.5 Mg/5 Ml Powder For Oral Suspension

Class 2 Recall on Co-Amoxiclav 125 Mg/31.25 Mg/5 Ml & 25 Mg/62.5 Mg/5 Ml Powder For Oral Suspension

Sandoz Ltd. have been notified of a potential packaging problem relating to poor seal adherence which could cause clumping of the powder within the bottle. A poor bottle seal could lead to degradation of the clavulanic acid within the powder and could potentially render the product ineffective..

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code Product Description Supplier Affected Batch
1086271 CO-AMOXICLAV SF 125/31.25MG SANDOZ LTD HT6202
HT7923
1117290 CO-AMOXICLAV 31/125MG/5ML SANDOZ LTD HT6202
HT7923
1086289 CO-AMOXICLAV 250/62MG SANDOZ LTD HT6202
HT7923
1117308 CO-AMOXICLAV SF 250/62.5MG SANDOZ LTD HT6202
HT7923

For enquiries relating to stock returns please contact Sandoz Limited Customer Services on 01276 698607 or email sales.sandoz-gb@sandoz.com

For Medical information enquiries, please contact Sandoz Medical Information Team on 01276 698101or email sandozgb@EU.propharmagroup.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.